SIGN UP
LOG IN
News
CTLT
56.08
-0.39%
-0.22
Weekly Report: what happened at CTLT last week (0408-0412)?
Weekly Report · 19h ago
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S. The company is developing the next generation of weight loss and diabetes drugs. Novo has been established as a leader in the obesity market. Eli Lilly and Co. And Novo will remain the two entrenched players in this duopoly.
Benzinga · 3d ago
BUZZ-BMO starts Novo Nordisk US shares with "overweight', Street-high PT
BMO Capital Markets starts Novo Nordisk's U.S.-listed shares with "outperform" and a Street-high PT of $163. The Danish drugmaker's stock gains 1% to $126.66. EU drug regulator found evidence that a class of diabetes drugs are linked to suicidal thoughts. BMO raises Eli Lilly's US shares to $900.
Reuters · 3d ago
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
TipRanks · 3d ago
Guru Fundamental Report for CTLT - Benjamin Graham
NASDAQ · 4d ago
Top 10 best performing S&P 500 health care stocks of 2024
19 of the 65 health care stocks within the S&P 500 have topped the broader market's performance in 2024. The health care sector traditionally has been seen as a defensive sector. The top 10 best performing health care companies in 2024 are all in the Health Care sector.
Seeking Alpha · 5d ago
Health Care Sector Update for 04/08/2024: ALNY, LEGN, JNJ, NVO, CTLT, XLV, IBB
NASDAQ · 04/08 13:28
UPDATE 1-Novo Nordisk parent refiles US application on Catalent deal
Novo Nordisk refiles application to U.S. FTC for approval of $16.5 billion deal to buy manufacturing subcontractor Catalent. Novo Nordisk Foundation said last month it agreed to buy Catalent to boost output of Wegovy drug. Catalent would sell three of its fill-finish sites to Novo for $11 billion.
Reuters · 04/08 10:28
NOVO NORDISK FOUNDATION: WE HAVE REFILED APPLICATION TO U.S. FEDERAL TRADE COMMISSION FOR APPROVAL OF CATALENT ACQUISITION AFTER INFORMAL DISCUSSION
Reuters · 04/08 09:55
Weekly Report: what happened at CTLT last week (0401-0405)?
Weekly Report · 04/08 09:07
MEDIA-Ares, Blue Owl lead $4.8 bln private debt for Catalent deal - Bloomberg News
Reuters · 04/05 20:47
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)
TipRanks · 04/05 07:50
Catalent Price Target Maintained With a $63.50/Share by Stephens & Co.
Dow Jones · 04/04 14:36
Stephens & Co. Reiterates Equal-Weight on Catalent, Maintains $63.5 Price Target
Benzinga · 04/04 14:26
Invenra To Collaborate With Catalent To Co-Discover Novel Bispecific ADCs
Benzinga · 04/02 17:59
Weekly Report: what happened at CTLT last week (0325-0329)?
Weekly Report · 04/01 09:07
Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues
Healthcare Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues. The Health Care Select Sector SPDR Fund ETF rose 8.32% in the first quarter of 2024. Eli Lilly (LLY) saw the biggest growth in the healthcare index.
Seeking Alpha · 03/30 16:13
International Companies Drive Diabesity Innovation
Diabetes and obesity markets are large and growing, with an estimated total long-term addressable market of $100 billion in the US alone. Denmark's Novo Nordisk and US-based Eli Lilly are leading pharmaceutical companies in the development of GLP-1-based treatments for diabetes and obesity. There is potential for global market expansion as millions of people are obese or at risk for diabetes but not receiving treatment.
Seeking Alpha · 03/29 13:59
Weekly Report: what happened at CTLT last week (0318-0322)?
Weekly Report · 03/25 09:07
Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Novo Nordisk announced plans to invest $556 million to expand its Tianjin production facility. BeiGene was approved to market a new drug in the US.
Seeking Alpha · 03/24 11:15
More
Webull provides a variety of real-time CTLT stock news. You can receive the latest news about Catalent Inc through multiple platforms. This information may help you make smarter investment decisions.
About CTLT
Catalent, Inc. is engaged in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. The Company’s Biologics segment provides development and manufacturing of biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells (iPSCs); oncolytic viruses, and vaccines. It also provides formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges, and analytical development and testing services for large molecules. The Company’s Pharma and Consumer Health segment comprises capabilities for complex oral solids, softgel formulations, Zydis fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms, and clinical trial development and supply services.